Positive
●
Reuters
●
20 days ago
Swiss drugmaker Novartis' drug Kisqali helped extend survival for women with a form of high-risk, early-stage breast cancer, cutting their risk of death by 19% after six years, according to trial data presented at the European Society for Medical Oncology congress in Madrid on Friday.